Hookipa Pharma Stock Cash Per Share
| HOOK Stock | USD 0.92 0.03 3.37% |
Hookipa Pharma's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Hookipa Stock price.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Hookipa Pharma Company Cash Per Share Analysis
Hookipa Pharma's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Hookipa Pharma Cash Per Share | 2.16 X |
Most of Hookipa Pharma's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hookipa Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Hookipa Pharma has a Cash Per Share of 2.16 times. This is 50.34% lower than that of the Biotechnology sector and 50.12% lower than that of the Health Care industry. The cash per share for all United States stocks is 56.89% higher than that of the company.
Hookipa Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hookipa Pharma's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hookipa Pharma could also be used in its relative valuation, which is a method of valuing Hookipa Pharma by comparing valuation metrics of similar companies.Hookipa Pharma is currently under evaluation in cash per share category among its peers.
Hookipa Fundamentals
| Return On Equity | -1.06 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (8.85) % | ||||
| Current Valuation | (28.88 M) | ||||
| Shares Outstanding | 9.8 M | ||||
| Shares Owned By Insiders | 19.27 % | ||||
| Shares Owned By Institutions | 34.13 % | ||||
| Number Of Shares Shorted | 35.8 K | ||||
| Price To Earning | 12.06 X | ||||
| Price To Book | 0.32 X | ||||
| Price To Sales | 1.15 X | ||||
| Revenue | 43.95 M | ||||
| Gross Profit | (50.47 M) | ||||
| EBITDA | (40.85 M) | ||||
| Net Income | (43.5 M) | ||||
| Cash And Equivalents | 117.92 M | ||||
| Cash Per Share | 2.16 X | ||||
| Total Debt | 875 K | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 5.48 X | ||||
| Book Value Per Share | 2.71 X | ||||
| Cash Flow From Operations | (76.98 M) | ||||
| Short Ratio | 0.57 X | ||||
| Earnings Per Share | (5.85) X | ||||
| Price To Earnings To Growth | (0.19) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 82 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 10.8 M | ||||
| Total Asset | 82.55 M | ||||
| Retained Earnings | (412.76 M) | ||||
| Working Capital | 56.01 M | ||||
| Current Asset | 26.61 M | ||||
| Current Liabilities | 25.01 M | ||||
| Net Asset | 82.55 M |
About Hookipa Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hookipa Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hookipa Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hookipa Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Hookipa Pharma Piotroski F Score and Hookipa Pharma Altman Z Score analysis. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.